The global bullous keratopathy market is expected to register a CAGR of 4.3% from 2023 to 2033, reaching a valuation of US$ 427.54 Million in 2023, as per a recently published Future Market Insights report. For the assessment period of 2023 to 2033, a CAGR of 4.3% is expected, with a closing value of US$ 650 million. The rising prevalence of ophthalmic diseases, such as keratoconus, Fuchs dystrophy, and infectious keratitis, is the key factor propelling the industry’s growth. According to the NCBI report, approximately 10-15% of patients diagnosed with keratoconus require to undergo a corneal implant procedure at some point.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16131
Corneal blindness is the third-leading cause of blindness after glaucoma and cataract affecting 10 million people globally. The most common cause of damage to endothelium layer of the cornea is eye surgery. Any kind of trauma, glaucoma, or inflammation from eye surgery can result in bullous keratopathy. Bullous keratopathy may occur in around 1% to 2% of patients undergoing cataract surgery, a nonsignificant number when you consider that approximately 10 million patients undergo cataract surgery worldwide each year.
Collagen-based bio-engineered artificial corneas used in Bullous Keratopathy have high demand in the market owing to their advantages, such as low cost, biocompatibility, and improved safety and effectiveness. There has been an increased focus of manufacturers to develop and launch new products. Currently, two products are in clinical trials and are expected to help the artificial cornea segment and overall industry growth over the forecast period. For instance, in 2022, Corneat Vision announced that its CorNeat KPro (artificial cornea) is undergoing clinical trials. This product is expected to receive marketing approval in 2024 which will aid in the market expansion of Bullous Keratopathy.
Corneal transplantation is the decisive treatment for Bullous Keratopathy as it revives the normal structure and function of endothelial cells. It can be done in the form of penetrating keratoplasty (PK), Descemet membrane endothelial keratoplasty (DMEK) or Descemet stripping automated endothelial keratoplasty (DSAEK). A cross-sectional national survey was conducted in Japan for 963 eyes with bullous keratopathy between 1999 and 2001 by members of the Japan Cornea Society. Demographic characteristics, type of surgery, complications, and postoperative outcomes were analyzed. Bullous keratopathy accounted for 24.2% (963 eyes) of total keratoplasties performed during the period (Shimazaki et al., 2007).
Key Takeaways:
- Global bullous keratopathy market likely to reach US$ 650 Million by 2033
- North America is expected to hold highest market share during the forecast period.
- Europe Bullous keratopathy market accounted for a 19.1% business share in 2022.
- The amniotic membrane transplantation is an effective method of treatment for bullous keratopathy and has beneficial influence on the process of corneal healing and the improvement of visual acuity and diminish subjective symptoms.
- By end-user, hospital segment dominated the market with revenue share of US$ 150 Million.
“With major breakthroughs in ophthalmology becoming evident, the scope for bullous keratopathy is expected to rise significantly. Moreover, healthcare practitioners are gravitating towards more precise surgeries to improve patient outcomes,” remarks an analyst at FMI.
Competitive Landscape
Key players in the Bullous Keratopathy market are- Hoffmann-La Roche Ltd, Regeneron, Pharmaceuticals, Inc., Pfizer, Inc., Bayer AG, Cellusion, CRSTEurope, Barraquer Eye Hospital, Planchard Eye & Laser Center, Medscape. Some recent developments in bullous Keratopathy market are:
- In September 2022: Celregen and Cellusion Inc. signed an exclusive license agreement for corneal endothelial cell regenerative therapy in Greater China.
- In July 2022: Carl Zeiss Meditec and Precise Bio announced a partnership in the development and commercialization of tissue-based implants for ophthalmology
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Embolization Coils market, presenting historical analysis from 2017 to 2021 and forecast statistics for the period of 2022 to 2032.
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-16131
Key Segments Profiled in the Bullous Keratopathy Market Industry Survey
Bullous Keratopathy Market by Therapies:
- Emmecell
- Drug Description
- Regulatory Milestones
- Safety and Efficiency
- Product Profile
- Cellusion
- Drug Description
- Other Development Activities
- Clinical Development
- Safety and Efficiency
- Product Profile
Bullous Keratopathy Market by End User:
- Hospitals
- Surgical Centers
Bullous Keratopathy Market by Treatment:
- Medical Management
- Lubricants
- Steroids
- Hyperosmotic agents
- Anti- Glaucoma drugs
- Antibiotics
- Amniotic Membrane Grafting (AMG)
- Annular Keratotomy
- Anterior Stromal Puncture
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
